CtrlK
LLY
NYSE
Pharmaceuticals
$1127.69
USD
+$18.79 (+1.69%)
Last close
Market Cap:
$1.06T
Volume:
2.8M
Previous Close
$1108.90
Day Range
$1114.00 - $1145.43
52 Week Range
$623.78 - $1182.73
Average Volume (10 Days)
2.9M
P/E Ratio
51.32
Dividend Yield
0.53%
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 50,000 full-time employees. The firm manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
CEO
Mr. David Ricks
Headquaters
Indianapolis, INDIANA, US
Founded
1970
Employees
50,000
Eli Lilly announced a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion in cash, including upfront payment and milestone-based payouts. The deal centers on Ajax's lead asset, AJ1-11095, a once-daily oral Type II JAK2 inhibitor currently in Phase 1 trials for myelofibrosis patients who no longer respond to existing treatments.
0
0
Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion, gaining rights to an experimental drug designed to improve treatment for blood cancers like myelofibrosis. The deal includes upfront cash plus milestone payments tied to clinical and regulatory achievements.
0
0
Eli Lilly's newly launched oral weight-loss drug Foundayo recorded 3,707 prescriptions in its second week on the market, trailing significantly behind competitor Novo Nordisk's Wegovy, which had 18,410 prescriptions in its second week. Analysts expressed concern over the modest uptake, though Lilly has cautioned that early data may not be comprehensive.
0
0
Eli Lilly's new oral weight-loss pill Foundayo recorded 3,707 U.S. prescriptions in its second week, significantly trailing Novo Nordisk's oral Wegovy, which had 18,410 prescriptions at the same point in its launch. The slow start has raised concerns about Lilly's ability to compete in the oral obesity drug market despite Foundayo's approval advantages and easier dosing.
0
0
PFE
Pfizer Inc
$23.67
-2.0%
